Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.
We report a case of severe hypercalcaemia in a 16-year-old patient, 24 weeks after immobilization for quadriplegia. The biochemical and histomorphometric parameters showed increased osteoclastic resorption and decreased osteoblastic formation. Hydration, chair sitting, salmon and porcine calcitonin, sodium etidronate were unable to normalize the hypercalcaemia. The new antiosteoclastic agent, 3-amino-1 hydroxypropylidene-1, 1-bisphosphonate (AHPrBP), was effective in normalizing serum calcium and biochemical parameters of osteoclastic activity within five days. Bone histomorphometry showed a marked reduction in osteoclastic activity after AHPrBP treatment, as well as a drastic depression of osteoblastic activity, presumably due to the reduction of bone turnover. This case represents to our knowledge, the first successful use of AHPrBP in the treatment of immobilization hypercalcaemia.
Varache
N
N
Service de Réanimation Médicale, Centre Hospitalier Régional, France.
Audran
M
M
Clochon
P
P
Lortholary
A
A
Bouachour
G
G
Alquier
P
P
Basle
M F
MF
D000293:Adolescent; D001706:Biopsy; D002118:Calcium / Q000097:blood; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007085:Ilium / Q000473:pathology; D007103:Immobilization / Q000009:adverse effects* / Q000502:physiology; D008297:Male; D010006:Osteoblasts / Q000473:pathology; D000077268:Pamidronate; D011782:Quadriplegia / Q000150:complications
D004164:Diphosphonates; D000077268:Pamidronate; D002118:Calcium